Mylotarg, fludarabine, cytarabine (Ara-C) and cyclosporine (MFAC) combination regimen in patients with CD33-positive primary resistant or relapsed acute myeloid leukemia (AML).

被引：0
|
作者：
Tsimberidou, AM [1 ]
Estey, E [1 ]
Cortes, J [1 ]
Thomas, D [1 ]
Garcia-Manero, G [1 ]
Faderl, S [1 ]
Verstovesk, S [1 ]
O'Brien, S [1 ]
Kantarjian, H [1 ]
Giles, F [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1317
引用
收藏
页码：339A / 340A
页数：2
相关论文
共 50 条
  • [31] ETOPOSIDE (VP-16) AND CYTOSINE-ARABINOSIDE (ARA-C) COMBINATION FOR SECONDARY AND RELAPSED ACUTE MYELOID-LEUKEMIA (AML)
    LAZZARINO, M
    MORRA, E
    INVERARDI, D
    ALESSANDRINO, EP
    BERNASCONI, P
    MERANTE, S
    BERNASCONI, C
    LEUKEMIA RESEARCH, 1986, 10 (01) : 111 - 111
  • [32] Clofarabine plus cytarabine (ARA-C) combination is active in newly diagnosed patients (pts) ≥ age 50 with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
    Faderl, S
    Gandhi, V
    Verstovsek, S
    Cortes, J
    Ravandi-Kashani, F
    Beran, M
    Garcia-Manero, G
    Koller, C
    O'Brien, S
    Ferrajoli, A
    Estrov, Z
    Kwari, M
    Plunkett, W
    Kantarjian, HM
    BLOOD, 2004, 104 (11) : 250A - 250A
  • [33] A Phase 1 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Ara-C in Patients with Relapsed or Refractory Acute Myeloid Leukemia
    DeAngelo, Daniel J.
    Fathi, Amir T.
    Werner, Lillian
    Avigan, David
    Luptakova, Katarina
    Wadleigh, Martha
    Steensma, David P.
    Hobbs, Gabriela Soriano
    Attar, Eyal C.
    Amrein, Philip C.
    Stone, Richard M.
    Ballen, Karen K.
    BLOOD, 2015, 126 (23)
  • [34] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
    MUFTI, GJ
    OSCIER, DG
    HAMBLIN, TJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
  • [35] CLADRIBINE(2-CDA) AND CYTARABINE(ARA-C) IS AN EFFECTIVE SALVAGE REGIMEN IN REFRACTORY/RELAPSED ACUTE MYELOID LEUKAEMIA IN CHILDREN
    Chinnaswamy, Girish
    Prasad, Maya
    Dwivedi, Pankaj
    Patil, Vijay
    Arora, Brijesh
    Banavali, Shripad
    PEDIATRIC BLOOD & CANCER, 2012, 59 (06) : 1040 - 1040
  • [36] A phase 1 trial of imatinib mesylate in combination with daunorubicin and cytarabine for patients for c-kit positive relapsed acute myeloid leukemia (AML)
    Advani, Anjali S.
    Sobecks, Ronald
    Sekeres, Mikkael A.
    Copelan, Ed
    Bates, Jennifer
    Tripp, Barbara
    Salvado, August
    Kalaycio, Matt
    BLOOD, 2007, 110 (11) : 276A - 276A
  • [37] Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).
    Zeidan, Amer
    Tan, Wei
    Wilding, Gregory
    Ford, LaurieAnn
    Hahn, Theresa
    Smiley, Shannon
    Battiwalla, Minoo
    McCarthy, Philip L.
    Wang, Eunice S.
    Wetzler, Meir
    BLOOD, 2008, 112 (11) : 350 - 351
  • [38] Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
    Candoni, Anna
    Martinelli, Giovanni
    Toffoletti, Eleonora
    Chiarvesio, Alexia
    Tiribelli, Mario
    Malagola, Michele
    Piccaluga, Pier Paolo
    Michelutti, Angela
    Simeone, Erica
    Damiani, Daniela
    Russo, Domenico
    Fanin, Renato
    LEUKEMIA RESEARCH, 2008, 32 (12) : 1800 - 1808
  • [39] Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse
    Sievers, EL
    Larson, RA
    Stadtmauer, EA
    Estey, E
    Löwenberg, B
    Dombret, H
    Karanes, C
    Theobald, M
    Bennett, JM
    Sherman, ML
    Berger, MS
    Eten, CB
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) : 3244 - 3254
  • [40] Phase I study of AVE9633, an antiCD33-maytansinoid immunoconjugate, administered as an intravenous infusion in patients with refractory/relapsed CD33-positive acute myeloid leukemia (AML).
    Giles, Francis
    Morariu-Zamfir, Rodica
    Lambert, John
    Verstovsek, Srdan
    Thomas, Deborah
    Ravandi, Farhad
    Deangelo, Dan
    BLOOD, 2006, 108 (11) : 216B - 216B
12345